These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 12847670)
21. Bias in its coat of many colors. Boers M J Rheumatol; 2001 Aug; 28(8):1747-8. PubMed ID: 11508573 [No Abstract] [Full Text] [Related]
22. Drug therapy in adolescents with rheumatic diseases. Schaller JG Rev Rhum Engl Ed; 1997 Oct; 64(10 Suppl):194S-195S. PubMed ID: 9385680 [No Abstract] [Full Text] [Related]
23. [Individualized therapy in treatment of rheumatic diseases]. Li ZG Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2449-50. PubMed ID: 17156668 [No Abstract] [Full Text] [Related]
24. Observations from the OMERACT Drug Safety Summit, May 2008. Simon LS; Strand CV; Boers M; Brooks PM; Henry D; Tugwell PS J Rheumatol; 2009 Sep; 36(9):2110-3. PubMed ID: 19738222 [TBL] [Abstract][Full Text] [Related]
26. Introduction to special section: biologic agents in the treatment of rheumatic diseases-the first decade. Yelin E; Katz P Arthritis Rheum; 2009 May; 61(5):559. PubMed ID: 19405010 [No Abstract] [Full Text] [Related]
27. [Individual and interdisciplinary treatment of rheumatic diseases in pregnancy]. Bolz M Dtsch Med Wochenschr; 2008 Nov; 133(46):2415. PubMed ID: 18988135 [No Abstract] [Full Text] [Related]
29. Dissemination and evaluation of the 3E initiative recommendations for use of methotrexate in rheumatic disorders: results of a study among 2233 rheumatologists. Gossec L; Bijlsma JW; Bombardier C; Canhão H; Devlin J; Edwards CJ; Hamuryudan V; Kvien TK; Leeb BF; Martín-Mola EM; Mielants H; Müller-Ladner U; Ostergaard M; Pereira IA; Ramos-Remus C; Zochling J; Dougados M Ann Rheum Dis; 2011 Feb; 70(2):388-9. PubMed ID: 20472594 [No Abstract] [Full Text] [Related]
30. Pharmacogenetic of antirheumatic treatments: clinical implications. Ferraccioli G; Tolusso B; De Santis M Pharmacogenomics J; 2007 Feb; 7(1):2-9. PubMed ID: 16702980 [TBL] [Abstract][Full Text] [Related]
31. How and when to use DMARDs. Simmons S Nurse Pract; 2010 Aug; 35(8):12-4. PubMed ID: 20644444 [No Abstract] [Full Text] [Related]
32. Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action. Katz SJ; Russell AS Curr Opin Rheumatol; 2011 May; 23(3):278-81. PubMed ID: 21448012 [TBL] [Abstract][Full Text] [Related]
37. Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis. Stokes DG; Kremer JM Semin Arthritis Rheum; 2003 Aug; 33(1):1-18. PubMed ID: 12920692 [TBL] [Abstract][Full Text] [Related]
38. Pharmacoepidemiology and rheumatic disorders. Chan KA; Hernandez-Diaz S Rheum Dis Clin North Am; 2004 Nov; 30(4):835-50, vii. PubMed ID: 15488696 [TBL] [Abstract][Full Text] [Related]
39. [Sulphasalazine: a promising drug in rheumatology]. Nasonov EL Klin Med (Mosk); 1997; 75(6):39-44. PubMed ID: 9273399 [No Abstract] [Full Text] [Related]
40. Toward a better understanding of methotrexate. Kremer JM Arthritis Rheum; 2004 May; 50(5):1370-82. PubMed ID: 15146406 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]